The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
Abstract
Objective: To investigate the impact of official recommendations regarding the management of latent tuberculosis (TB) infection on the rate of active TB in patients receiving treatment with tumor necrosis factor (TNF) antagonists. Methods: Data on active TB rates and on screening and treatment of latent TB infection were extracted from the BIOBADASER (Spanish Society of Rheumatology Database on Biologic Products), a registry of patients with rheumatic conditions treated with TNF antagonists. The rates of active TB among the BIOBADASER patients were compared with those in the background Spanish population, and BIOBADASER patients with rheumatoid arthritis (RA) were compared with a cohort of RA patients from the EMECAR (Morbidity and Clinical Expression of Rheumatoid Arthritis) study who were not treated with TNF antagonists and were followed up for 5 years. Results: Active TB developed in 34 patients, of whom 32 started taking TNF antagonists prior to the official recommendations on latent TB infection (pre‐OR) and 2 began treatment after the recommendations were issued (post‐OR). All cases of TB occurred during treatment with infliximab, and 28 of these patients had RA. Pre‐OR, the active TB rate in BIOBADASER patients was 20.9‐fold higher than in the background Spanish population, while RA patients in the BIOBADASER had rates 22.6‐ and 6.2‐fold higher than the background and EMECAR populations, respectively. Post‐OR, 324 patients with a tuberculin skin test result ≥5 mm and/or chest radiograph findings suggestive of past TB were treated for 9 months with isoniazid (INH). Post‐OR, active TB rates among the BIOBADASER patients decreased by 78% (incidence risk ratio [IRR] 0.22, 95% confidence interval [95% CI] 0.03–0.88; P = 0.008), while among RA patients in the BIOBADASER, the rate dropped by 83% and reached the EMECAR rate (IRR 1.0, 95% CI 0.02–8.2). There were no INH treatment–related hospitalizations or deaths. Conclusion: Strategies to treat latent TB infection that are tailored to the at‐risk population can effectively and safely lessen the likelihood of active TB in patients treated with TNF antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Gómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
Self-citationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
(2016) · Pediatric Clinical Practice Guidelines & Policies · doi:10.1542/9781610020190-part06-targeted · Cited by 920
Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
Arts, D. G. T. (2002) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m1087 · Cited by 597
When Tuberculosis Treatment Fails: A Social Behavioral Account of Patient Adherence
Sumartojo, E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.5.1311 · Cited by 468
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Wolfe, F., Michaud, K., Anderson, J., & Urbansky, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20009 · Cited by 431
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection: (548072006-001)
(2000) · PsycEXTRA Dataset · doi:10.1037/e548072006-001 · Cited by 322
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Mohan, A. K., Timothy, R. C., Block, J. A., Manadan, A. M., Siegel, J. N., & Braun, M. M. (2004) · Clinical Infectious Diseases · doi:10.1086/421494 · Cited by 303
Increased risk of tuberculosis in patients with rheumatoid arthritis.
Carmona, L., Hernández‐García, C., Vadillo, C., Pato, E., Balsa, A., González‐Álvaro, I., Belmonte, M. Á., Tena, X., & Sanmartí, R. (2003) · PubMed · Cited by 233
Self-citation
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“to reduce the incidence of TB disease include household contacts of active TB patients [55, 63], native Alaskan communities [64], residents of mental health facilities [65], persons with HIV infection [66–69], and individuals treated with TNF inhibitors [70, 71].”
BackgroundBeukelman, T., Patkar, N. M., Saag, K. G., Tolleson‐Rinehart, S., Cron, R. Q., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20460 · Cited by 834
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Mack, U., Migliori, G. B., Sester, M., Rieder, H. L., Ehlers, S., Goletti, D., Bossink, A., Magdorf, K., Hölscher, C., Kampmann, B., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00120908 · Cited by 591
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Self-citationKucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
Scott, D. L., & Kingsley, G. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmct055183 · Cited by 461
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F., & LoBue, P. A. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1510.090310 · Cited by 320
Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22600 · Cited by 302
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
Perez-Moreiras, J. V., Gomez-Reino, J. J., Maneiro, J. R., Perez-Pampin, E., Romo Lopez, A., Rodríguez Alvarez, F. M., Castillo Laguarta, J. M., del Estad Cabello, A., Gessa Sorroche, M., España Gregori, E., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.038 · Cited by 300
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Furst, D. E. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Winthrop, K. L. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0336 · Cited by 280
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Mycobacterial diseases and antitumour necrosis factor therapy in USA
Winthrop, K., Baxter, R., Liu, L., Varley, C., Curtis, Jr., Baddley, J., McFarland, B., Austin, D., Radcliffe, L., Suhler, E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200690 · Cited by 274
Interleukin-18 and the Pathogenesis of Inflammatory Diseases
Dinarello, C. A. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2006.09.013 · Cited by 252
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
Metadata
- Authors
- Carmona, L., Gómez‐Reino, J. J., Rodríguez‐Valverde, V., Montero, D., Pascual‐Gómez, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 52
- Issue
- 6
- Pages
- 1766-1772
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2131999276
- Cited by
- 656
- References
- 15
- FWCI
- 23.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.